Stockreport

Protalix BioTherapeutics advances Fabry disease and gout programs during 2025 [Yahoo! Finance]

Protalix BioTherapeutics, Inc. (DE)  (PLX) 
PDF Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) reported its 2025 financial results and outlined recent regulatory, clinical and commercial developments, including [Read more]